After a significant rally in June that saw the sector finally break through stubborn upward resistance levels that had been in place for a year and a half, biotech has spent July so far largely just consolidating these gainsThis is understandable, especially in light of dormant M&A activity and the fact that second-quarter earnings reports will no...
Read the full story and get access to the Real Money Pro trading floor.
There's no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.